Garibaldi Joins Synendos as Chief Medical Officer
Company - People | Jul 15, 2025 | Ysios Capital
Synendos Therapeutics, a biotech firm focused on neuropsychiatric and CNS disorders, has appointed Dr. George Garibaldi as Chief Medical Officer. Dr. Garibaldi, with extensive experience at major pharmaceutical companies such as Roche, Novartis, and Janssen, is tasked with guiding Synendos' lead drug candidate, SYT-510, as it progresses from Phase 1 to Phase 2 clinical trials. Garibaldi's dedication to innovative psychiatric treatments aligns with Synendos' mission to address the underserved mental health sector. The company, backed by Ysios Capital, aims to leverage its novel Selective Endocannabinoid Re-uptake Inhibitors (SERIs), which they believe offer potential breakthroughs in treatment efficacy and chronic tolerability.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- Switzerland – Basel, Switzerland is the location of Synendos Therapeutics' operations as mentioned in the article.
Industry
- Biotechnology – The article discusses Synendos Therapeutics, which is developing therapies for neuropsychiatric and CNS disorders, a focus area within biotechnology.
- Pharmaceuticals – Dr. George Garibaldi's previous experience at major pharmaceutical companies highlights the intersection of pharmaceutical development within the biotechnology industry.
- Healthcare – The focus on advancing mental and brain health treatments places this article within the broader healthcare industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Synendos Therapeutics | Target Company | Company | A clinical-stage biotechnology company developing therapies for neuropsychiatric disorders. |
| Ysios Capital | Private Equity Backer | Company | A PE firm backing Synendos Therapeutics in its development ambitions. |
| Dr. George Garibaldi | Chief Medical Officer | Person | A seasoned psychiatrist and neuroscientist known for leading clinical programs in CNS disorders. |
| Andrea Chicca | CEO, Synendos | Person | CEO of Synendos Therapeutics, involved in the appointment of Dr. Garibaldi. |